कंपनी का अवलोकन
SI-BONE, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry where it develops procedural solutions for compromised bone using patented titanium implants and specialized instrumentation. The company leverages deep expertise in biomechanical design to create anatomy-specific applications that serve both domestic and international markets, addressing complex orthopedic needs through advanced procedural technologies. This medical device firm employs a workforce of 376 individuals, supporting its global operations and product development initiatives across the United States and abroad. With a market capitalization of $615.22M and annual revenue reaching $200.92M, the company holds a significant valuation that reflects its position as a substantial player in the orthopedic implant space, indicating strong investor interest despite current profitability challenges.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $200.92M, yet it recorded a net income of -$18,904,000 and an EBITDA of -$16,560,000, revealing a substantial gap between top-line sales and bottom-line earnings driven by high operational costs and expenses. Free cash flow stood at -$4,801,750, which suggests that the company is currently burning cash, likely due to heavy capital expenditure on research, development, and expansion efforts rather than generating immediate liquidity from operations. The gross margin is exceptionally high at 79.6%, indicating efficient production and strong pricing power on its implant products, while the operating margin of -4.4% and profit margin of -9.4% highlight significant overhead pressures and non-recurring expenses impacting overall profitability. On the balance sheet, the company holds $147.82M in cash against $36.69M in debt, resulting in a debt-to-equity ratio of 20.67, which presents a complex picture of a cash-rich entity with substantial leverage relative to equity. The current ratio of 8.55 demonstrates robust short-term liquidity, suggesting the company has ample assets to cover its immediate liabilities without risk of insolvency. Return on Equity is -11.0% and Return on Assets is -6.0%, metrics that indicate management has not yet generated returns on the capital invested, reflecting the early-stage or high-growth phase of the business model where reinvestment outweighs profit generation.
मूल्यांकन आकलन
Valuation metrics for SI-BONE, Inc. present a mixed picture, with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E stands at -36.52, implying that future earnings expectations are also currently negative or that the market is pricing in a long turnaround period. The price-to-book ratio is 3.43, indicating that the market values the company at more than three times its book value, suggesting investors are willing to pay a premium for its intellectual property and future growth potential despite current losses. Alternative valuation measures such as the price-to-sales ratio of 3.06 and an EV/EBITDA of -30.44 further illustrate that the stock is priced based on revenue multiples rather than profitability, a common characteristic for high-growth medical device firms. The stock has traded between a 52-week low of $12.15 and a high of $21.89, placing the current price context within a range that shows significant volatility but also a clear ceiling set by recent market peaks. The beta of 0.77 indicates that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market swings compared to large-cap technology or financial stocks.
Growth & Income
Revenue growth year-over-year is 15.0%, demonstrating strong top-line expansion, whereas earnings growth is N/A, which implies that profitability is not yet tracking with revenue growth and that the company is still in an investment-heavy phase. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning SI-BONE reinvests all of its earnings back into the business to fund operations and R&D rather than distributing cash to shareholders. The absence of a dividend payout reflects the company's strategy of prioritizing growth and market share acquisition over immediate income generation for investors. Overall, the financial profile shows a company with impressive revenue expansion and a strong cash position, but one that remains unprofitable and relies on internal funding or external capital to sustain its high-burn rate until operational efficiencies can drive positive earnings.